Regulatory shifts enabling compounded peptide access
The recent relaxation of regulatory barriers by the Health and Human Services has fundamentally altered the landscape for compounded peptide distribution, creating a fertile ground for new market entrants. On November 18, 2026, telehealth giants Hims & Hers Health and Noom capitalized on this shift by rolling out dedicated peptide programs, signaling a decisive move into the booming longevity sector. Hims & Hers Health, Inc. launched its Peptides+ platform across the United States on November 19, 2026, offering clinically guided therapies that include compounded forms of sermorelin, glutathione, NAD+, vitamin B-12, and L-carnitine. This strategic expansion allows the company to provide personalized treatment plans while navigating the complex approval landscape, as these specific compounds remain unapproved by the FDA. The simultaneous announcement at HLTH 2026 underscored a coordinated industry effort to capture market share through accessible, direct-to-consumer models that bypass traditional pharmaceutical channels.
Also worth reading: How does the healthcare SaaS market trends impact B2B care-coordination and patient-pulse solutions for clinics and care networks? · How does improved software sentiment impact Veeva Systems share price? · What is the impact of Health Catalyst's Form 4 filing by CEO Simeon Kohl on September 14?
This regulatory easing has empowered care networks to integrate these novel therapies into broader wellness strategies, impacting how clinics coordinate patient care. For B2B care-coordination platforms like those serving getpulse.care, the influx of compounded peptides necessitates robust tracking mechanisms to monitor patient outcomes and safety profiles. The absence of FDA approval for these specific compounds introduces significant variability in efficacy and safety, requiring enhanced patient-pulse monitoring systems to ensure quality care. As telehealth providers expand their offerings, care networks must adapt their operational frameworks to handle the increased complexity of managing compounded therapies alongside traditional treatments. This evolution highlights the critical need for scalable, data-driven solutions that can support the growing demand for personalized, non-FDA-approved interventions while maintaining rigorous standards of care coordination and patient safety across diverse clinical settings.
Telehealth giants expanding into longevity therapies
Hims & Hers Health launched its Peptides+ platform across the U.S. on November 19, 2026, following a regulatory shift by the HHS that eased restrictions for compounding pharmacies. This move allows the telehealth giant to offer compounded forms of sermorelin, glutathione, NAD+, vitamin B-12, and L-carnitine, none of which hold FDA approval. Simultaneously, Noom joined the fray at the HLTH 2026 conference, signaling a coordinated entry into this booming sector. These launches directly address the unresolved market question of how major digital health players will leverage regulatory ambiguities to capture share. By bypassing traditional drug approval pathways, these companies are creating a new distribution channel for unapproved longevity therapies, fundamentally altering how patients access experimental treatments.
The impact on the broader market is significant, as it legitimizes compounded peptides through established telehealth infrastructure. Hims & Hers explicitly admits there is more to learn about efficacy, yet proceeds with personalized treatment plans guided by clinicians. This strategy forces competitors to reconsider their own product roadmaps, potentially accelerating the adoption of non-FDA approved substances. For care networks, this development raises critical questions about liability and standard of care. As these platforms scale, they may overwhelm existing clinical support systems, necessitating robust coordination tools. The convergence of direct-to-consumer marketing with compounded pharmacy supply chains creates a complex ecosystem where patient safety and regulatory compliance remain primary concerns for healthcare providers and insurers alike.
Clinical guidance models for unapproved compounds
The recent entry of Hims & Hers Health and Noom into the peptide market signals a significant shift in how telehealth platforms manage unapproved compounds. On November 18, 2026, these companies announced launches of compounded therapies including sermorelin, glutathione, and NAD+, explicitly acknowledging limited efficacy data. This move followed a regulatory easing by the HHS, allowing compounding pharmacies to distribute such drugs more broadly. Hims & Hers subsequently introduced Peptides+ across the U.S., offering personalized treatment plans for eligible customers. Noom joined this trend during the HLTH 2026 conference, positioning itself alongside these direct-to-consumer giants. These launches collectively expand access to longevity-focused interventions that lack FDA approval, creating a new category of digital health services.
For care coordination platforms like those serving clinics and care networks, this development introduces complex challenges. Providers must navigate the clinical guidance of unapproved substances while maintaining safety standards. The absence of FDA validation requires robust patient monitoring and clear communication about experimental nature. As these platforms scale, integrating real-time patient pulse data becomes essential to track outcomes and adverse events. Care networks need structured models to evaluate efficacy and safety without relying on traditional regulatory frameworks. This evolving landscape demands innovative approaches to risk management and patient education, ensuring that telehealth expansions do not compromise clinical integrity or patient trust in emerging therapeutic areas.
Patient safety concerns regarding efficacy data
The recent launches of peptide programs by Hims & Hers Health and Noom have significantly disrupted the telehealth market, driven by regulatory shifts that eased restrictions on compounding pharmacies. On November 18, 2026, these direct-to-consumer giants announced their entry into the booming peptide sector at the HLTH conference, capitalizing on a newly favorable Health and Human Services stance. Hims & Hers subsequently launched its Peptides+ longevity platform across the United States on November 19, offering compounded forms of sermorelin, glutathione, NAD+, vitamin B-12, and L-carnitine. This move expanded their personalized health care offerings, yet it introduced substantial uncertainty regarding clinical validation. While the companies position these treatments as part of advanced wellness strategies, the absence of FDA approval for these specific compounded agents creates a complex landscape for consumers and providers alike.
This rapid expansion raises critical questions about patient safety, particularly concerning the efficacy data supporting these new therapies. Hims & Hers explicitly admitted on November 18 that there remains more to learn about the effectiveness of these compounds. Consequently, care networks and clinics must navigate a landscape where popular telehealth platforms are distributing unapproved substances alongside clinically guided treatment plans. The lack of robust clinical trials for these specific compounded peptides means that safety profiles are not fully established. As Noom and Hims & Hers compete for market share, the medical community faces the challenge of addressing potential adverse effects and ensuring that patients understand the limitations of efficacy data. This gap underscores the urgent need for rigorous monitoring and transparent communication to protect patient health amidst this commercial surge.
Market competition among direct-to-consumer platforms
The competitive landscape for direct-to-consumer health platforms shifted significantly in mid-November 2026 as major telehealth giants Hims & Hers Health and Noom simultaneously launched peptide programs. This strategic move followed a regulatory change by the HHS, which eased restrictions for compounding pharmacies to offer specific drugs like BPC-157. Hims & Hers Health, trading under the ticker HIMS, introduced its Peptides+ longevity treatment platform across the United States on November 18, 2026. This new specialty offering provides clinically guided peptide therapies and personalized treatment plans to eligible customers. Concurrently, Noom joined the fray at the HLTH 2026 conference, signaling a broader industry pivot toward managing the booming demand for these specialized health interventions.
These launches introduce complex clinical and operational challenges for care networks. While Hims & Hers expanded its personalized health care portfolio by including compounded forms of sermorelin, glutathione, NAD+, vitamin B-12, and L-carnitine, the company admitted there is more to learn about efficacy. Notably, none of these compounded treatments are approved by the FDA. For B2B care-coordination SaaS providers, this surge in unapproved, telehealth-delivered therapies creates urgent needs for robust patient-pulse monitoring systems. Clinics must now track outcomes and safety data for these novel regimens to ensure proper care coordination. The rapid market expansion demands sophisticated digital infrastructure to manage patient compliance and adverse event reporting, highlighting the critical role of integrated software in navigating this evolving therapeutic landscape.
Hims vs Noom Peptide Program Comparison
| Feature | Hims & Hers Health | Noom | Market Impact |
|---|---|---|---|
| Launch Date | November 2026 | November 2026 | Expanded telehealth access |
| Product Focus | Peptides+, compounded therapies | New peptide offerings | Increased competition |
| Regulatory Status | Non-FDA approved compounds | Direct-to-consumer model | Shift in care coordination |
| Availability | Nationwide U.S. rollout | Nationwide U.S. rollout | Market growth acceleration |